Amphastar Pharmaceuticals
AMPH
119 hedge funds and large institutions have $474M invested in Amphastar Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 42 increasing their positions, 49 reducing their positions, and 23 closing their positions.
1.32% more ownership
Funds ownership: 51% → 52.31% (+1.3%)
1% less capital invested
Capital invested by funds: $478M → $474M (-$4.05M)
11% less funds holding
Funds holding: 134 → 119 (-15)
14% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 49
61% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 23
91% less call options, than puts
Call options by funds: $32K | Put options by funds: $372K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$8.17M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$5.45M |
| 3 |
Goldman Sachs
New York
|
+$4.22M |
| 4 |
BlackRock
New York
|
+$2.61M |
| 5 |
Renaissance Technologies
New York
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$3.17M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.62M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.29M |
| 4 |
MCM
Matarin Capital Management
New York
|
-$1.95M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.41M |
AMPH Hedge Fund Activity: Q4 2019 in Review
119 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q4 2019, worth a combined $474M — down 0.85% from $478M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of AMPH and 9 opened new positions — a net loss of 14 holders — while 49 trimmed existing stakes and 42 added.
The largest buyer was Invesco, adding an estimated $8.17M. The largest seller was Nuveen, cutting an estimated $3.17M.
- 119 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q4 2019, down from 134 in Q3 2019.
- Funds reported $474M of Amphastar Pharmaceuticals stock for Q4 2019, down 0.85% quarter-over-quarter.
- 9 funds opened new Amphastar Pharmaceuticals positions in Q4 2019 and 23 closed out, a net change of -14 holders.
- The largest Amphastar Pharmaceuticals buyer in Q4 2019 was Invesco, an estimated $8.17M added.
- The largest Amphastar Pharmaceuticals seller in Q4 2019 was Nuveen, an estimated $3.17M sold.
Based on aggregated 13F filings for Q4 2019.